Literature DB >> 10303913

Evaluating new treatments and diagnostic technologies in obstetrics. Practical problems, ethics, and solutions.

R J Lilford.   

Abstract

This article develops arguments for the use of decision theory, rather than intuition, to determine the size of trials. It is wrong to expect doctors to ignore personal preferences in favor of clinical experiments unless the trial is capable of showing differences in treatment effect that would influence clinical practice substantially. It follows from our analysis that if delta (the treatment effect that the trial is designed to detect) is sufficient to alter clinical practice, then the alpha and beta errors of a trial should be equal. This applies even if a new treatment is to be compared with conventional therapy or if a treatment with high "costs" is compared with a less invasive or more inexpensive method.

Mesh:

Year:  1989        PMID: 10303913     DOI: 10.1017/s0266462300007510

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  2 in total

1.  At what level of collective equipoise does a clinical trial become ethical?

Authors:  N Johnson; R J Lilford; W Brazier
Journal:  J Med Ethics       Date:  1991-03       Impact factor: 2.903

2.  Clinical trials and rare diseases: a way out of a conundrum.

Authors:  R J Lilford; J G Thornton; D Braunholtz
Journal:  BMJ       Date:  1995-12-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.